

NYRx, the Medicaid Drug Program, Notice to Providers: Medicaid Coverage of Ifosfamide

October 8, 2026

Due to the current critical shortage of Ifosfamide for Injection products in the United States (U.S.) market, SteriMax USA Inc. (SteriMax), is coordinating with the U.S. Food and Drug Administration (FDA) to [temporarily import unapproved Ifosfamide for Injection](#), 1g/vial currently marketed in China.

Currently, no entity other than SteriMax USA Inc., NJ, or its distributor GlobalRX, NC, is authorized by the FDA to import or distribute imported Ifosfamide for Injection in the U.S.

Effective immediately, GlobalRX will distribute the following presentations of imported Ifosfamide for Injection to address the critical shortage:

Imported Ifosfamide for Injection				
Product Name	Quantity	Batch/Lot Details	Expiry Date	NDC
Ifosfamide for Injection, 1g per vial	Five vials per carton	FA2B6007A	June 21, 2029	21586-021-02
		FA2B6008BA	June 25, 2029	Labeled: 21586-0211-2

Contact Information

The NYRx Education & Outreach Call Center is available by phone at 1-833-967-7310 or by email at NYRxEO@primetherapeutics.com from 8:00 AM to 5:00 PM ET, Monday through Friday, excluding holidays.